Compare Erasca Inc. Common Stock (ERAS) vs Rocket Companies Inc. Class A Common Stock (RKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Erasca Inc. Common Stock vs Rocket Companies Inc. Class A Common Stock — how do they compare? Erasca Inc. Common Stock trades at $14.6 (market cap $5.17B), while Rocket Companies Inc. Class A Common Stock trades at $10.68 (market cap $29.82B). The key difference: Rocket Companies Inc. Class A Common Stock is far larger — about 5.8× Erasca Inc. Common Stock's market cap, and Erasca Inc. Common Stock is trading nearer its 52-week high, Rocket Companies Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 1 Days and Rocket Companies Inc. Class A Common Stock for 0 Days on average.
| ERAS | RKT | |
|---|---|---|
Market Cap | $5.17B | $29.82B |
Volume | 5,313,379 | 46,995,062 |
Sector | Health | Financials |
52-Week High | $22.47 | $23.44 |
52-Week Low | $2.20 | $10.53 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.95B | $59.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ERAS trades at $14.78, down 4.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $22.50. The company is a clinical-stage oncology firm with no revenue, reporting a net loss of $124.55 million in 2025, but holds significant liquidity and has three potential registration-enabling trials ahead. Recent news highlights FDA Fast Track designation for its lead candidate ERAS-0015.
The outlook is speculative, driven by clinical trial progress; upside exists if trials succeed, but high cash burn and shareholder investigations pose substantial risks. Investment hinges on binary outcomes from drug development, making it suitable only for risk-tolerant investors focused on biotech.
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Erasca Inc. Common Stock
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →About Rocket Companies Inc. Class A Common Stock
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →
